Number of patients at risk
194
194
148
111
112
66
81
45
18
6
233
243
171
150
128
89
97
53
46
25
6
3
0
0
0
1
Nivolumab
Docetaxel
292
290
Overall Survival
CheckMate 057: Nivolumab vs Docetaxel in Previously Treated NSQ NSCLC
24
Based on a February 18, 2016 database lock; minimum follow-up: 2 years
Borghaei H, et al. Presented at the American Society of Clinical Oncology 2016 Annual Meeting; June 3–7, 2016; Chicago, IL, USA. Abstract 9025.
2-year OS = 29%
2-year OS = 16%
Months
20
40
60
80
100
0
6
12
18
24
30
39
3
9
15
21
27
33
36
Nivolumab
Docetaxel
1-year OS = 51%
1-year OS = 39%
1
5
Δ12%
0
OS (%)
Δ13%
Events
Nivoluma
b
(n = 292)
n
Docetaxe
l
(n = 290)
n
Differenc
e
n
0−3
months
59
44
15
3−6
months
39
48
[9]
